Home Sectors Healthcare Stock in the Spotlight: LivaNova (NASDAQ: LIVN)

Stock in the Spotlight: LivaNova (NASDAQ: LIVN)

SHARE

LivaNova trades as part of the medical devices industry and is part of the healthcare sector. The company CEO is Damien McDonald. LivaNova is a medical technology company formed by the merger of Sorin S.p.A, engaged in the treatment of cardiovascular diseases, and Cyberonics, a medical device company with core expertise in neuromodulation.

Previous Intraday Trading Performance:

The LIVN stock showed a previous change of -2.41% with an open at 75.26 and a close of 73.05. It reached an intraday high of 75.64 and a low of 72.64.

SeekingAlpha:  Stoke Therapeutics Files Proposed Terms For IPO

Liquidity:

The stock has a market cap of $3.5b with 48.3m shares outstanding, of which the float is 46.9m shares. Trading volume reached 336,284 shares compared to its average volume of 503,095 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, LivaNova shares returned -1.42% and in the past 30 trading days it returned 6.04%. Over three months, it changed -23.00%. In one year it has changed -26.79% and within that year its 52-week high was 131.54 and its 52-week low was 64.80. LIVN stock is 12.73% above its 52 Week Low.

Our calculations show a 200 day moving average of 97.18 and a 50 day moving average of 73.21. Currently LIVN stock is trading -24.83% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Stoke Therapeutics Files Proposed Terms For IPO

Earnings:

The last annual fiscal EPS for the company was reported at -3.91 that ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is 0.53. The TTM EPS is 3.04, which comes to a TTM PE of 24.03.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/01/2019): -0.31
4thQtr of 2018 (Reported on 02/27/2019): -4.34
3rdQtr of 2018 (Reported on 10/31/2018): -0.15
2ndQtr of 2018 (Reported on 08/01/2018): 0.31
1stQtr of 2018 (Reported on 05/02/2018): 0.27

Base on our calculations, the intrinsic value per share is 91.84, which means it is possibly undervalued and has a margin of safety of 20.46%.

Indicators to Watch:

The current calculated beta is 0.37.

SeekingAlpha:  Merger Arbitrage Analysis And Spread Performance – June 9, 2019

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is -13.84%, return on assets is -8.59%, profit margin is -19.70%, price-to-sales is 3.27 and price-to-book is 2.43.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 0  :Past Performance Score
 3  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.

LEAVE A REPLY

Please enter your comment!
Please enter your name here